open access

Vol 9, No 3-4 (2008): Practical Diabetology
Review articles (submitted)
Published online: 2008-07-04
Get Citation

Treatment and monitoring post transplant diabetes mellitus in patients after kidney transplantation

Roman Junik, Barbara Brzezińska
Diabetologia Praktyczna 2008;9(3-4):152-156.

open access

Vol 9, No 3-4 (2008): Practical Diabetology
Review articles (submitted)
Published online: 2008-07-04

Abstract

People who are a kidney transplant recipients are at high risk of developing diabetes (PTDM). This can lead to significant complications being a major cause of death. So early diagnosis and effective treatment are necessary to improve the prognosis and quality of patient’s live. After transplantation, an aggressive program should include life style intervention such as exercise training and reduce obesity to minimize the risk of PTDM. When diabetes develops, the dose of corticosteroids should be reduced as soon as possible. Any reduction in corticosteroid dose should be balanced against the possible increased risk of graft rejection. Transplant recipients who develop PTDM while receiving the tacrolimus may also benefit from a switch to the less diabetogenic agent cyclosporine. In patients with fasting blood glucose values of 130-180 mg/dl, the initial intervention is dietary restriction of concentrated sugars. Patients, who are refractory to dietary control or those with fasting blood glucose values of 181-250 mg/dl are usually started an oral hypoglycemic agents ( the choice of drugs should be made by the physician for each person ). People with fasting blood glucose values > 250 mg/dl or those who are unresponsive to oral hypoglycaemic agents need insulin. Good controlling of hypertension and hyperlipidaemia is also important. Use statins and ACE inhibitors is particularly helpful.
The prevention and treatment of PTDM is an important part of the care of people who undergo kidney transplantation.

Abstract

People who are a kidney transplant recipients are at high risk of developing diabetes (PTDM). This can lead to significant complications being a major cause of death. So early diagnosis and effective treatment are necessary to improve the prognosis and quality of patient’s live. After transplantation, an aggressive program should include life style intervention such as exercise training and reduce obesity to minimize the risk of PTDM. When diabetes develops, the dose of corticosteroids should be reduced as soon as possible. Any reduction in corticosteroid dose should be balanced against the possible increased risk of graft rejection. Transplant recipients who develop PTDM while receiving the tacrolimus may also benefit from a switch to the less diabetogenic agent cyclosporine. In patients with fasting blood glucose values of 130-180 mg/dl, the initial intervention is dietary restriction of concentrated sugars. Patients, who are refractory to dietary control or those with fasting blood glucose values of 181-250 mg/dl are usually started an oral hypoglycemic agents ( the choice of drugs should be made by the physician for each person ). People with fasting blood glucose values > 250 mg/dl or those who are unresponsive to oral hypoglycaemic agents need insulin. Good controlling of hypertension and hyperlipidaemia is also important. Use statins and ACE inhibitors is particularly helpful.
The prevention and treatment of PTDM is an important part of the care of people who undergo kidney transplantation.
Get Citation

Keywords

kidney recipient; post transplant diabetes mellitus; treatment of hyperglycaemia

About this article
Title

Treatment and monitoring post transplant diabetes mellitus in patients after kidney transplantation

Journal

Clinical Diabetology

Issue

Vol 9, No 3-4 (2008): Practical Diabetology

Pages

152-156

Published online

2008-07-04

Bibliographic record

Diabetologia Praktyczna 2008;9(3-4):152-156.

Keywords

kidney recipient
post transplant diabetes mellitus
treatment of hyperglycaemia

Authors

Roman Junik
Barbara Brzezińska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl